Alpha Centric Advisors LLC Gilead Sciences, Inc. Transaction History
Alpha Centric Advisors LLC
- $97.4 Million
- Q4 2024
A detailed history of Alpha Centric Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 10,562 shares of GILD stock, worth $1.27 Million. This represents 1.0% of its overall portfolio holdings.
Number of Shares
10,562
Previous 3,500
201.77%
Holding current value
$1.27 Million
Previous $293,000
232.76%
% of portfolio
1.0%
Previous 0.25%
Shares
9 transactions
Others Institutions Holding GILD
# of Institutions
2,315Shares Held
992MCall Options Held
9.23MPut Options Held
9.49M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.5MShares$7.14 Billion0.28% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.56 Billion0.78% of portfolio
-
Capital Research Global Investors Los Angeles, CA31.1MShares$3.73 Billion0.72% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $150B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...